Literature DB >> 3160660

Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

P Ames, D DesJardins, G B Pier.   

Abstract

We used an in vitro opsonophagocytic killing assay to measure the functional activity of antibody directed at the mucoid exopolysaccharide (MEP) antigen expressed by Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Rabbit antibodies raised to purified MEP were able to mediate phagocytic killing in the presence of human peripheral blood leukocytes and a low level (final concentration, 0.3%) of fresh normal human serum as a complement source. No bacterial killing was observed when peripheral blood leukocytes, antiserum, or complement was omitted. Specificity of the antibody for the MEP antigen was shown by adsorption and inhibition assays. Affinity-purified antibody to MEP also mediate phagocytic killing. These data indicate that antiphagocytic properties attributable to MEP can be overcome by specific antibody.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3160660      PMCID： PMC262011          DOI： 10.1128/iai.49.2.281-285.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  16 in total

1.  Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria.

Authors:  J Verhoef; P K Peterson; P G Quie
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

2.  Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature.

Authors:  P A di Sant'agnese; P B Davis
Journal:  Am J Med       Date:  1979-01       Impact factor: 4.965

3.  Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.

Authors:  L S Young; D Armstrong
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

4.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

5.  Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay.

Authors:  L E Bryan; A Kureishi; H R Rabin
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

6.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.

Authors:  R E Hancock; L M Mutharia; L Chan; R P Darveau; D P Speert; G B Pier
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

7.  Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.

Authors:  G B Pier; D M Thomas
Journal:  J Infect Dis       Date:  1983-08       Impact factor: 5.226

8.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors:  G B Pier
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

9.  Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.

Authors:  G B Pier; W J Matthews; D D Eardley
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

10.  Antiphagocytic Effect of Slime from a Mucoid Strain of Pseudomonas aeruginosa.

Authors:  S Schwarzmann; J R Boring
Journal:  Infect Immun       Date:  1971-06       Impact factor: 3.441
View more
  31 in total

1.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum.

Authors:  T R Anderson; T C Montie
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

3.  Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.

Authors:  Victoria L Campodónico; Nicolás J Llosa; Martha Grout; Gerd Döring; Tomás Maira-Litrán; Gerald B Pier
Journal:  Infect Immun       Date:  2009-12-07       Impact factor: 3.441

4.  Hypochlorite scavenging by Pseudomonas aeruginosa alginate.

Authors:  D B Learn; E P Brestel; S Seetharama
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

5.  Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.

Authors:  M J Preston; A A Gerçeker; M E Reff; G B Pier
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Inhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal antibodies, and antibiotics.

Authors:  G T Mai; J G McCormack; W K Seow; G B Pier; L A Jackson; Y H Thong
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

Review 8.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

9.  Respiratory-mucin inhibition of the opsonophagocytic killing of Pseudomonas aeruginosa.

Authors:  S Vishwanath; R Ramphal; C M Guay; D DesJardins; G B Pier
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

10.  Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.

Authors:  G B Pier; S Takeda; M Grout; R B Markham
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.